Pioneering a new class of anti-cancer immunotherapy for robust tumor-targeted
T-cell immunity

Photos for Life is a charity photo bank, where all of the models are cancer patients and survivors.

Home

EpiThany is dedicated to the advancement of innovative therapies that can improve the lives of cancer patients. Our focus is on developing tumor vaccines that drive
Th1 (tumor-eradicating) immune responses without
stimulating competitive Th2 (tumor-tolerant) responses.

EpiThany technology enables the targeting of myriad tumor antigens
across a spectrum of cancers, yielding a deep pipeline of Th1-selective anti-cancer vaccines.

News //

See all news

Noteworthy

EpiThany, Inc. was founded in 2014 in Seattle to consolidate the discovery technology and clinical stage assets of the Tumor Vaccine Group at the University of Washington

Innovative

EpiThany vaccines target a previously untapped wealth of tumor antigens, with its leading-edge vaccines targeting multiple antigens simultaneously

Collaborative

We leverage a strong heritage of translational research from the UW Tumor Vaccine Group, and develop strategic combinations of our vaccines with promising new immune modulators